Faricimab  (Synonyms: 法瑞西单抗; RG7716)

Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO)^{[1][2][3][4][5]}.

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Humanized

Angiopoietin-2, VEGF-A^[1]

Faricimab (2000 ng/mL, 37 天) 经药物配制和储存长达 37 天，其双特异性抗原结合特性没有受损，并且具有结构完整的 IgG1 Fc 片段^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Faricimab (10 mg/kg, 腹膜注射, 两次, 隔一周, 持续 1-5 周) 减少 JR5558 小鼠自发性脉络膜新生血管 (sCNV)，病变渗漏面积和视网膜下 Iba1⁺、CD11b⁺、CD45⁺ 细胞浸润^[4]。
Faricimab (3 μg/μL, 玻璃体注射, 单次剂量, 持续 48 小时) 在视网膜缺血/再灌注 (I/R) 损伤小鼠模型中防止 I/R 损伤小鼠视网膜通透性和细胞死亡^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1607793-29-2

液体

Colorless to light yellow

法瑞西单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG1-kappa-lambda with half-IG VL-CH1/VH-CK crossover

• 
  Immobilized Faricimab can bind VEGF165 Protein, Human.The EC₅₀ for this effect is 3.418 ng/mL.
• 
  Immobilized Faricimab can bind Human Angiopoietin-2/ANGPT2 Protein (His Tag).The EC₅₀ for this effect is 4.10 ng/mL.

• [1]. Sahni J, et al. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. Ophthalmology. 2019 Aug;126(8):1155-1170.  [Content Brief]

  [2]. Nicolò M, et al. Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases[J]. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.  [Content Brief]

  [3]. Penha FM, et al. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME[J]. Int J Retina Vitreous. 2024 Jan 17;10(1):5.  [Content Brief]

  [4]. Canonica J, et al. Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia/reperfusion[J]. Front Cell Neurosci. 2023 Jun 12;17:1192464.  [Content Brief]

  [5]. Jørstad ØK, et al. Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties[J]. Int J Retina Vitreous. 2023 Nov 7;9(1):65.  [Content Brief]